Clinical responses to smallpox vaccine in vaccinia-naive and previously vaccinated populations: Undiluted and diluted Lancy-Vaxina vaccine in a single-blind, randomized, prospective trial

Journal of Infectious Diseases

Volumn 192, Issue 6, 2005, Pages 1066-1070

  Kim, Sung Han ^a   Yeo, Sang Gu ^a   Jang, Hee Chang ^b   Park, Wan Beom ^b   Lee, Chang Seop ^b   Lee, Ki Deok ^b   Kim, Hong Bin ^b   Kim, Nam Joong ^b   Kim, Young Taek ^c   Jee, Youngmee ^a   Cho, Haewol ^a   Oh, Myoung Don ^b   Choe, Kang Won ^b  

^a Korea National Institute of Health   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Korea Centers for Disease Control and Prevention   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

LANCY VAXINA VACCINE; NEUTRALIZING ANTIBODY; SMALLPOX VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; AXILLA; AXILLARY PAIN; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DILUTION; DRUG RESPONSE; FATIGUE; FEMALE; HEADACHE; HUMAN; INJECTION PAIN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MYALGIA; NORMAL HUMAN; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVACCINATION; SINGLE BLIND PROCEDURE; SKIN DEFECT; SMALLPOX; VACCINATION; VACCINIA; VACCINIA VIRUS; VIRUS SHEDDING;

ADULT; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; MALE; NEUTRALIZATION TESTS; SINGLE-BLIND METHOD; SKIN; SMALLPOX VACCINE; VACCINATION; VACCINIA VIRUS; VIRUS SHEDDING;

EID: 24644449093     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/432765     Document Type: Article

References (14)

1. Frey SE, Couch RB, Tacket CO, et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002; 346:1265-74.
2. Ed-Ad B, Roth Y, Winder A. The persistence of neutralizing antibodies after revaccination against smallpox. J Infect Dis 1990; 161:446-8.
3. Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003; 9:1131-7.
4. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003; 171:4969-73.
5. Frey SE, Newman FK, Yan L, Lottenbach KR, Belshe RB. Response to smallpox vaccine in persons immunized in the distant past. JAMA 2003; 289:3295-9.
6. Orr N, Forman M, Marcus H, et al. Clinical and immune responses after revaccination of Israeli adults with the Lister strain of vaccinia virus. J Infect Dis 2004; 190:1295-302.
7. Centers for Disease Control and Prevention. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2001; 50:1-25.
8. Graham BS, Belshe RB, Clements ML, et al. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. J Infect Dis 1992; 166:244-52.
9. Talbot TR, Ziel E, Doersam JK, LaFleur B, Tollefson S, Edwards KM. Risk of vaccinia transfer to the hands of vaccinated persons after small-pox immunization. Clin Infect Dis 2004; 38:536-41.
10. Frey SE, Newman FK, Cruz J, et al. Dose-related effects of smallpox vaccine. N Engl J Med 2002; 346:1275-80.
11. Talbot TR, Stapleton JT, Brady RC, et al. Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial. JAMA 2004;292:1205-12.
12. Arita I. Duration of immunity after smallpox vaccination: a study on vaccination policy against smallpox bioterrorism in Japan. Jpn J Infect Dis 2002; 55:112-6.
13. Worthington M. Role of antibody in recovery from severe vaccinia virus infection. Clin Infect Dis 2003; 37:864-5.
14. Cassimatis DC, Atwood JE, Engler RM, Linz PE, Grabenstein JD, Vernalis MN. Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol 2004; 43:1503-10.